Ibrexafungerp

(Brexafemme®)

Ibrexafungerp

Drug updated on 12/19/2023

Dosage FormTablet (oral; 150 mg)
Drug ClassTriterpenoid antifungals
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (VVC).

Product Monograph / Prescribing Information

Document TitleYearSource
Brexafemme (ibrexafungerp tablets) Prescribing Information.2022SCYNEXIS Inc., Jersey City, NJ

Randomized Controlled Trials


Sex Distribution:

F:100%
M:0%
820Subjects

Year:

2023

Source:Journal of Women’s Health


Sex Distribution:

F:100%
M:0%
376Subjects

Year:

2021

Source:Clinical Infectious Diseases


Sex Distribution:

F:100%
M:0%
455Subjects

Year:

2021

Source:BJOG: An International Journal of Obstetrics and Gynaecology